These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36465977)

  • 21. Alkaptonuria in Russia.
    Soltysova A; Kuzin A; Samarkina E; Zatkova A
    Eur J Hum Genet; 2022 Feb; 30(2):237-242. PubMed ID: 34504318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
    Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Untargeted NMR Metabolomics Reveals Alternative Biomarkers and Pathways in Alkaptonuria.
    Grasso D; Geminiani M; Galderisi S; Iacomelli G; Peruzzi L; Marzocchi B; Santucci A; Bernini A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raman Spectroscopy identifies differences in ochronotic and non-ochronotic cartilage; a potential novel technique for monitoring ochronosis.
    Taylor AM; Jenks DD; Kammath VD; Norman BP; Dillon JP; Gallagher JA; Ranganath LR; Kerns JG
    Osteoarthritis Cartilage; 2019 Aug; 27(8):1244-1251. PubMed ID: 31022456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in management of alkaptonuria (invited review; best practice article).
    Ranganath LR; Jarvis JC; Gallagher JA
    J Clin Pathol; 2013 May; 66(5):367-73. PubMed ID: 23486607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review.
    Ranganath LR; Norman BP; Gallagher JA
    J Inherit Metab Dis; 2019 Sep; 42(5):776-792. PubMed ID: 31282009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.
    Bernini A; Petricci E; Atrei A; Baratto MC; Manetti F; Santucci A
    Sci Rep; 2021 Nov; 11(1):22562. PubMed ID: 34799606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.
    Braconi D; Bianchini C; Bernardini G; Laschi M; Millucci L; Spreafico A; Santucci A
    J Inherit Metab Dis; 2011 Dec; 34(6):1163-76. PubMed ID: 21874298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological and Ultrastructural Characterization of Alkaptonuric Tissues.
    Millucci L; Bernardini G; Spreafico A; Orlandini M; Braconi D; Laschi M; Geminiani M; Lupetti P; Giorgetti G; Viti C; Frediani B; Marzocchi B; Santucci A
    Calcif Tissue Int; 2017 Jul; 101(1):50-64. PubMed ID: 28271171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.
    Wilson PJM; Ranganath LR; Bou-Gharios G; Gallagher JA; Hughes JH
    JIMD Rep; 2021 Mar; 58(1):52-60. PubMed ID: 33728247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.
    Cox TF; Ranganath L
    J Inherit Metab Dis; 2011 Dec; 34(6):1153-62. PubMed ID: 21744089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoothened-antagonists reverse homogentisic acid-induced alterations of Hedgehog signaling and primary cilium length in alkaptonuria.
    Gambassi S; Geminiani M; Thorpe SD; Bernardini G; Millucci L; Braconi D; Orlandini M; Thompson CL; Petricci E; Manetti F; Taddei M; Knight MM; Santucci A
    J Cell Physiol; 2017 Nov; 232(11):3103-3111. PubMed ID: 28019670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins.
    Braconi D; Millucci L; Bernini A; Spiga O; Lupetti P; Marzocchi B; Niccolai N; Bernardini G; Santucci A
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):135-146. PubMed ID: 27865997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
    J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
    J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alkaptonuria is a novel human secondary amyloidogenic disease.
    Millucci L; Spreafico A; Tinti L; Braconi D; Ghezzi L; Paccagnini E; Bernardini G; Amato L; Laschi M; Selvi E; Galeazzi M; Mannoni A; Benucci M; Lupetti P; Chellini F; Orlandini M; Santucci A
    Biochim Biophys Acta; 2012 Nov; 1822(11):1682-91. PubMed ID: 22850426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition.
    Taylor AM; Preston AJ; Paulk NK; Sutherland H; Keenan CM; Wilson PJ; Wlodarski B; Grompe M; Ranganath LR; Gallagher JA; Jarvis JC
    Osteoarthritis Cartilage; 2012 Aug; 20(8):880-6. PubMed ID: 22542924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria.
    Thorpe SD; Gambassi S; Thompson CL; Chandrakumar C; Santucci A; Knight MM
    J Cell Physiol; 2017 Sep; 232(9):2407-2417. PubMed ID: 28158906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.